Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition

Erik Mossdorf1,2,4,5, Marcel Stoeckle4,5, Emmanuel G Mwaigomole1,2, Evarist Chiweka1,2, Patience L Kibatala1, Eveline Geubbels3, Honoraty Urassa2, Salim Abdulla3, Luigia Elzi5, Marcel Tanner4, Hansjakob Furrer6, Christoph Hatz4 and Manuel Battegay5*

Abstract

Background: Data on combination antiretroviral therapy (cART) in remote rural African regions is increasing.

Methods: We assessed prospectively initial cART in HIV-infected adults treated from 2005 to 2008 at St. Francis Designated District Hospital, Ifakara, Tanzania. Adherence was assisted by personal adherence supporters. We estimated risk factors of death or loss to follow-up by Cox regression during the first 12 months of cART.

Results: Overall, 1,463 individuals initiated cART, which was nevirapine-based in 84.6%. The median age was 40 years (IQR 34-47), 35.4% were males, 7.6% had proven tuberculosis. Median CD4 cell count was 131 cells/μl and 24.8% had WHO stage 4. Median CD4 cell count increased by 61 and 130 cells/μl after 6 and 12 months, respectively. 215 (14.7%) patients modified their treatment, mostly due to toxicity (56%), in particular polyneuropathy and anemia. Overall, 129 patients died (8.8%) and 189 (12.9%) were lost to follow-up. In a multivariate analysis, low CD4 cells at starting cART were associated with poorer survival and loss to follow-up (HR 1.77, 95% CI 1.15-2.75, p = 0.009; for CD4 <50 compared to >100 cells/μl). Higher weight was strongly associated with better survival (HR 0.63, 95% CI 0.51-0.76, p < 0.001 per 10 kg increase).

Conclusions: cART initiation at higher CD4 cell counts and better general health condition reduces HIV related mortality in a rural African setting. Efforts must be made to promote earlier HIV diagnosis to start cART timely. More research is needed to evaluate effective strategies to follow cART at a peripheral level with limited technical possibilities.

Keywords: HIV-1 antiretroviral therapy, treatment outcome, rural, Tanzania

Background

WHO launched the ambitious "3 by 5" strategy in 2003 following the dramatically improved prognosis of HIV-infected patients receiving combination antiretroviral therapies (cART) in industrialized countries [1,2]. This public health approach aimed to introduce cART at large scale for resource-constrained countries [3] carrying most of the HIV attributable disease burden [4]. WHO's policy of “universal access” followed in 2007 [5] based on publications reflecting comparable clinical and immunological outcomes under cART from different resource-limited countries [6-17]. The number of people receiving cART in low- and middle-income countries has increased 13-fold since 2004 and by the end of 2009, an estimated 5.2 million people were receiving cART, which represent 36% of those who need treatment [4].

In 2007, the HIV-prevalence in Tanzania was estimated to be 5.7% with about 1,867,918 HIV infected Tanzanian children and adults [18,19]. The HIV incidence slowed to about 3.4/1000 person-years between 2004 and 2008 [4].
In response to the HIV epidemic, the Government of Tanzania launched the “National HIV/AIDS Care and Treatment Plan 2003 - 2008” - an initiative to prevent HIV/AIDS and to provide treatment and care for patients living with HIV/AIDS [20]. By the end of 2007, 127,895 HIV infected persons received cART with an increase to 154,468 only one year later [4,19]. As in other countries, the Tanzanian treatment plan was initiated first in large cities at university and/or referral hospitals. However, a significant part of HIV-infected Tanzanians live in rural regions [21,22] and cART evaluations from rural care and treatment centres in sub-Saharan Africa, and in particular Tanzania, are still scarce [13,23-27].

We aimed to assess the clinical and immunological response to cART in a rural treatment centre in Tanzania emphasizing immunological recovery and risk factors of death or loss to follow-up during the first year after starting cART.

Methods
Study design and setting
We analyzed data of a local prospective cohort study of HIV-infected individuals at the Care and Treatment Centre of St. Francis Designated District Hospital (SFDDH) in Ifakara, Tanzania. All HIV-infected adults initiating cART between 1st January 2005 and 20th December 2008 at the SFDDH were included in this study.

The SFDDH is the most important health care facility in the rural Kilombero and Ulanga District of the Morogoro Region in Southern Tanzania, providing treatment and care for a population of about 600,000 inhabitants and an estimated 30,000 patients living with HIV/AIDS [5]. Established in 2004, the Chronic Disease Clinic at St. Francis Designated District Hospital was the first rural clinic accredited to be a Care and Treatment Centre of the National AIDS Control Programme (NACP) in the whole of Tanzania [28]. By December 2008, the Care and Treatment Centre at SFDDH had enrolled 3,440 patients living with HIV/AIDS. Of these, 2,445 were followed-up on a permanent basis, and 1,491 treated with cART. Each patient taking cART had a personal adherence supporter [28]. In addition, all patients presenting with tuberculosis were tested for HIV, enabling thereby early diagnosis and follow-up of HIV/tuberculosis co-infected patients. After initiation of cART and clinical stabilization, patients were referred to a Refilling Centre closer to their living place facilitating adherence, and returned to the Care and Treatment Centre only on a three-monthly basis.

Outcome measures and cART
In the survival analysis, we included all HIV-infected patients who died from all causes within the first year after starting cART. We also considered all patients lost to follow-up as failures, since a meta-analysis of Brinkhof et al. [29] showed that in rural sub-Saharan African cohorts up to 20 to 69% of patients lost to follow-up that could be retraced had died.

All patients were treated according to NACP guidelines [30] which are based on the 2002 WHO recommendations and the 2007 revision of the WHO guidelines [31]. Individuals were eligible for cART if they: (a) had a WHO stage 4 disease, (b) had proven tuberculosis and a CD4 cell count between 200 and 350 cells/μl, (c) had a CD4 cell count below <200 cells/μl or (d) were pregnant irrespective of CD4 cell count. In addition, every patient with a WHO stage 3 and more or a CD4 cell count <200 cells/μl received prophylaxis with co-trimoxazole 400/80 mg/day.

Patients were followed up every month until resolution of clinical symptoms of an AIDS defining illness and to the point of achieving two consecutively increasing CD4 cell counts under cART. Thereafter, appointments were scheduled on a three-monthly basis. At each visit, signs of tuberculosis were actively investigated. Laboratory controls included a blood cell count and chemistry two weeks after initiation of cART and a CD4 cell count after 3 months and every 6 months thereafter. Measurement of HIV-RNA was not available for the present study. cART switches due to toxicity or other reasons were performed in line with the NACP [30]. The same applied for treatment failures defined as a new or recurrent WHO stage 4 condition, decrease of CD4 cell count to pre-therapy baseline (or below), a 50% fall from the on-treatment peak value or persistent CD4 levels below 100 cells/μl.

Adherence support
Each patient receiving cART designated a personal adherence supporter - mostly a family member or any other trustworthy person living in the vicinity of the patient. The supporters received counseling about cART and side effects, provided assistance in taking cART throughout the study period and accompanied the patient at cART initiation and from then on request at follow-up visit.

Patients with cART who missed visits were contacted or traced by home based care volunteers where possible.

Data collection and definitions
Data was collected prospectively using standardized record forms completed at each follow-up visit including information on the clinical course, occurrence of tuberculosis, WHO stage, adherence, laboratory results and treatment history. Data was entered into the NACP and the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) databases. Quality control was performed by double data entering and cross-checking procedures.
Staging of HIV disease followed the case and stage definition according to WHO guidelines [32]. Tuberculosis was diagnosed and treated following WHO guidelines within the framework of the National Tuberculosis and Leprosy Control Programme [33].

cART defined as a combination of at least 3 antiretroviral drugs was prescribed following the recommendations of the NACP [30]. The first-line regime consisted of a fixed dose combination of nevirapine 200 mg plus lamivudine 150 mg and stavudine 30 mg (individuals > 60 kg 40 mg till end of December 2006) twice daily. Similar immunological and virological outcomes were found between the two stavudine doses in patients weighing more than 60 kg in an African operational cohort at 6 months [34].

Anemia was defined as haemoglobin < 12 g/dl and was seen as a contraindication for prescribing zidovudine. Hepatitis was diagnosed if transaminases increased > 5 times the upper norm.

Loss to follow-up was defined as not showing up on two consecutive visits, i.e. for a period of 6 months.

**Statistical analysis**

Basic socio-demographic characteristics, co-infection with tuberculosis, HIV clinical stage, CD4 cell count, and antiretroviral treatment were compared using the Chi-square test or Fisher’s exact test for categorical variables, and the Mann-Whitney test for continuous variables. Cox proportional hazard models were used to investigate factors associated with survival and loss to follow-up after starting cART. All patients were censored at 12 months after starting cART if no death or loss to follow-up had occurred. Patients who were lost to follow-up were considered as failures and censored at the last visit date. The proportional hazards assumption was checked using the Schoenfeld test. Logistic regression was used to explore risk factors of being lost to follow-up during the first year of cART and as well as predictors of treatment modification. Multivariate models were built using a forward stepwise approach, adding each factor significant at the level of 0.1 and other factors defined in the literature as prognostic in the model one by one. The final model was examined for interaction using the likelihood ratio test.

All analyses were performed using STATA™ software version 9.2 for Windows (StataCorp, College Station, Texas).

**Ethical approval**

The research and ethical clearance was obtained from the Medical Research Coordination Board of the National Institute for Medical Research, Tanzania, through the Tanzania Commission for Science & Technology and from the Ethical Review Board of the Cantons Baselstadt and Baselland, Switzerland.

Written informed consent was obtained from all participants enrolled in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO).

**Results**

Overall, 1,463 treatment-naïve, HIV-infected adults initiated cART between 1st January 2005 and 20th December 2008. The median age was 40 years (interquartile range [IQR] 34-47), 35.4% were males, and 7.6% had confirmed tuberculosis. 2.6% of the female individuals were pregnant. The median CD4 cell count was 131 cells/µl (IQR 54-234) and 24.3% had a WHO clinical stage 4. Patients co-infected with tuberculosis tended to start cART at higher CD4 cell counts than patients without tuberculosis (142 versus 117 cells/µl; p = 0.060).

Antiretroviral therapy consisted of a nevirapine-based regimen in 83.1% of individuals. 75% of all patients were started on nevirapine/lamivudine/stavudine, 8.1% on nevirapine/lamivudine/zidovudine, 13.3% on efavirenz/lamivudine/zidovudine, 1.8% on efavirenz/lamivudine/stavudine, and 1.8% on other drug combinations.

General characteristics of the study population according to the outcome at 12 months are listed in Table 1.

**Response to cART**

The median CD4 cell count increase was 61 cells/µl (IQR 10-167) and 130 cells/µl (IQR 43-222) after 6 and 12 months, respectively. In particular, at 6 months and 12 months 49.9% and 70.1% of patients with available data had CD4 cell counts > 200 cells/µl, respectively, compared with only 23.6% at starting cART. During the follow-up, the median increase in body weight was 3 kg (IQR 0-8), and 115 out of 181 patients (63.5%) with available data experienced a change of activity from either bedridden or ambulant to working. Overall, 129 patients (8.8%) died and 189 (12.9%) were lost to follow-up during the first year of cART.
Risk factors of poor survival at 12 months after starting cART

In a multivariate model adjusted for age, gender, body weight, CD4 cell count, the presence of tuberculosis and antiretroviral regimen, risk factors for poor survival were lower CD4 cell counts at starting cART (HR 1.77, 95% CI 1.157-2.72, p = 0.009 for CD4 cell count <50 compared with >100 cells/μl) (Table 2 and Figure 1). In contrast, higher body weight was strongly associated with better survival (HR 0.63, 95% CI 0.51-0.76, p < 0.001 per 10 kg increase) (Table 2). Risk factors for poor survival and loss to follow-up during the first year of cART are listed in Table 2.

Treatment modification

During the follow-up, 215 individuals (14.7%) changed their antiretroviral treatment after a median time of 133 days (IQR 58-371). The most frequent reason for modifying cART was toxicity to cART (56.2%), i.e. peripheral polyneuropathy in 26.8%, concern of potential drug-drug interactions related to antituberculous therapy in 23.2%, anemia in 13.9% of patients, and treatment failure in 6.7%. Among patients with treatment change due to toxicity, the use of stavudine was clearly associated with an increased risk of polyneuropathy (OR 28.7, 95% CI 3.85-214.34, p = 0.001), whereas all 26 patients who changed their treatment due to anemia were initiated on a zidovudine-containing regimen. Only one woman modified her initial, efavirenz-containing antiretroviral therapy due to pregnancy.

The immunological recovery at 12 months did not differ between patients who changed their treatment and those who did not (144 cells/μl [IQR 62-230] versus 122 cells/μl [IQR 33-222], p = 0.289). However, patients who changed cART showed a higher median increase in body weight than those who remained on their first regimen (5 kg [IQR 0.2-10] versus 3 kg [IQR 0-7], p = 0.003). No difference in the mortality rate was noted according to whether patients had changed their treatment (7.9% versus 9.8%, p = 0.388).

In a multivariate model adjusted for age, sex, CD4 cell count, body weight, presence of tuberculosis, and cART, an antiretroviral regimen containing efavirenz and zidovudine combined with lamivudine (odds ratio (OR) 1.80, 95% CI 1.11-2.90, p = 0.016, compared to a nevirapine based regimen) was the only risk factor of treatment modification within the first year of cART.

### Table 1 General characteristics of the adult study population (n = 1463) according to the outcome at 12 months after starting combination antiretroviral therapy

| Characteristics at 12 months | All patients N = 1463 | Death or lost to follow-up N = 318 | Alive and on cART N = 1145 | p-value dead vs. alive |
|-----------------------------|-----------------------|-----------------------------------|----------------------------|------------------------|
| **Median age, IQR**         | 40 34-47              | 40 33-48                          | 40 34-47                   | 0.913                  |
| **Males**                   | 518 35.4              | 130 40.9                          | 388 33.9                   | 0.021                  |
| **Marital status**          |                       |                                   |                            |                        |
| Single                      | 213 14.6              | 24 7.6                            | 189 16.5                   | <0.001                 |
| Married                     | 390 26.7              | 48 15.1                           | 342 29.9                   |                        |
| Divorced or Widowed         | 277 18.9              | 37 11.6                           | 240 21.0                   |                        |
| No information              | 583 39.8              | 209 65.7                          | 374 32.7                   |                        |
| **Median weight, IQR**      | 50 43-56              | 45 39-52                          | 51 44-57                   | <0.001                 |
| **Median hemoglobin, IQR**  | 95 8-11               | 8.8 7.4-10.7                      | 9.8 8.2-11.1               | <0.001                 |
| **WHO stage**               |                       |                                   |                            |                        |
| I                           | 162 11.1              | 11 3.5                            | 151 13.2                   | <0.001                 |
| II                          | 155 10.6              | 7 2.2                             | 148 12.9                   |                        |
| III                         | 279 19.0              | 31 9.8                            | 248 21.7                   |                        |
| IV                          | 197 13.5              | 40 12.6                           | 157 13.7                   |                        |
| No information              | 670 45.8              | 229 72.0                          | 441 38.5                   |                        |
| **Median CD4 cell count, IQR** | 131 54-234          | 80 27-156                         | 130 60-205                 | <0.001                 |
| **Tuberculosis**            |                       |                                   |                            |                        |
| Proven                      | 111 7.6               | 19 6.0                            | 92 8.0                     | <0.001                 |
| Suspected                   | 538 36.8              | 62 19.5                           | 476 41.6                   |                        |
| **cART**                    |                       |                                   |                            |                        |
| Nevirapine-based            | 890 60.8              | 130 40.9                          | 760 66.4                   | <0.001                 |
| Efavirenz-based             | 162 11.1              | 23 7.2                            | 139 12.1                   |                        |
| No information              | 411 28.1              | 165 51.9                          | 246 21.5                   |                        |
| **Distance to clinic**      |                       |                                   |                            |                        |
| <10 km                      | 710 48.5              | 143 45.0                          | 567 49.5                   | 0.561                  |
| 10-50 km                    | 271 18.5              | 66 20.7                           | 205 17.9                   |                        |
| 50-100 km                   | 276 18.9              | 59 18.5                           | 217 19.0                   |                        |
| >100 km                     | 134 9.2               | 33 10.4                           | 101 8.8                    |                        |
| No information              | 72 4.9                | 17 5.4                            | 55 4.8                     |                        |
Table 2 Risk factors for poor survival and loss to follow-up during the first year of cART, hazard ratios (HR), univariate and multivariate analysis

| Characteristics | Univariate analysis | Multivariate analysis§ |
|-----------------|---------------------|------------------------|
|                 | HR  | 95% CI  | p-value | HR# | 95% CI  | p-value |
| Age, per 10 years older | 0.98 | 0.87-1.09 | 0.669 | 0.97 | 0.80-1.17 | 0.760 |
| Female | 0.77 | 0.62-0.97 | 0.025 | 0.77 | 0.52-1.15 | 0.201 |
| Weight, per 10 kg increase | 0.61 | 0.54-0.69 | <0.001 | 0.63 | 0.51-0.76 | <0.001 |
| Tuberculosis | - | - | - | - | - | - |
| Absent | 1* | - | - | 1* | - | - |
| Suspected | 0.49 | 0.37-0.68 | <0.001 | 0.63 | 0.44-1.10 | 0.082 |
| Confirmed | 0.73 | 0.45-1.16 | 0.180 | 1.28 | 0.70-2.33 | 0.421 |
| CD4 cell count | - | - | - | - | - | - |
| >100 | 1* | - | - | 1* | - | - |
| 50-100 | 1.50 | 1.07-2.11 | 0.018 | 1.37 | 0.82-2.29 | 0.230 |
| <50 | 2.31 | 1.77-3.04 | <0.001 | 1.77 | 1.15-2.72 | 0.009 |
| cART | - | - | - | - | - | - |
| Nevirapine-based | 1* | - | - | 1* | - | - |
| Efavirenz-based | 1.13 | 0.71-1.79 | 0.607 | 0.91 | 0.54-1.52 | 0.712 |

* reference category.
# adjusted for all variables listed in the table.
§ Global test of proportional hazards assumption (Schoenfeld): p = 0.248.

Loss to follow-up
During the study period, 189 (12.9%) patients were lost to follow-up. In a multivariate model adjusted for age, sex, marital status, distance between living place and the clinic, confirmed tuberculosis and CD4 cell count, independent risk factors of loss to follow-up were a CD4 cell count below 100 cells/μl at starting cART (OR 2.55, 95% CI 1.45-4.50, p = 0.001) and living more than 100 km away from the clinic (OR 3.02, 95% CI 1.40-6.56, p = 0.005).

Death
Overall, 129 patients (8.8%) died during the first year of antiretroviral therapy. 56 (75.7%) of all patients with a known cause of death died of an AIDS-defining event (tuberculosis in 30.4%, bacterial pneumonia in 19.6%, *Pneumocystis jirovecii* pneumonia in 14.3%, waisting syndrome in 10.7%, Kaposi sarcoma in 10.7%, cerebral toxoplasmosis in 7.1%, cervical/anal cancer in 3.6% and candida osophagitis in 3.6%). 18 individuals died of other causes (gastroenteritis in 5, cardiovascular disease in 4, severe anemia in 3, malaria in 2, peritonitis in 2, rectum carcinoma in 1 and road accident in 1 patient). The cause of death remained unknown in 55 patients.

Time to death or loss to follow-up during the first year after starting cART according to the baseline CD4 cell count cells/μl is shown in Figure 1.
cART possibly influencing this latter analysis by a selection bias.

Study population and treatment response
The age-sex distribution of this cohort was comparable to most studies from sub-Saharan Africa with about one third being male [12,14,23,35-39]. The median CD4 cell count at cART initiation, i.e. 131 cells/μl, was slightly higher than in some settings [8,14,23,35-38]. Two cohorts [12,40] from Zambia and Rwanda and a recent systematic review in sub-Saharan Africa [41] showed a high variation of CD4 cell counts at baseline with mostly comparable CD4 cell counts at baseline. Patients co-infected with tuberculosis tended to start cART at higher CD4 cell counts, possibly reflecting earlier diagnosis of HIV in symptomatic patients. The median CD4 cell increase of 130 cells/μl after 12 months of cART was comparable to the immunological recovery reported in the large cART-LINC Collaboration multinational analysis and the Rwandan National Programme [36,37,40], but was lower than in smaller cohorts [12,14,38,39,42-44]. Importantly, CD4 cells surpassed the 200 CD4 cell level in most individuals in our cohort.

Treatment change and toxicity
Due to differences in study modeling, in the observation period and in assessing the reason for switching, comparison of the rate of treatment change was prone to misinterpretation in the different studies evaluated [8,14,35,43,45,46]. This was additionally enhanced by the fact that toxicity due to stavudine accumulated over time whereas toxicity to nevirapine, efavirenz, lamivudine and zidovudine occurred earlier in the course of cART. The range of cART switches lay between 8%-21.9% in sub-Saharan Africa [8,14,35,43,45,46]. However, we found a higher rate of polyneuropathy despite a similar use of stavudine. Possibly, the high consumption of cassava in the catchment area of our clinic known to induce endemic polyneuropathy may have increased this toxicity [47-50]. A regimen containing efavirenz and zidovudine combined with lamivudine was associated with a 2-fold higher risk of treatment modification within the first year of cART, possibly due to an enhanced effect of zidovudine on a pre-existing anemia in a hyperendemic area of malaria.

Risk factors for poor survival
CD4 cells of less than 50 cells/μl and low body weight at starting cART reflecting late presentation were independent risk factors for poor survival in our cohort, findings shared with other cohorts [8,12,14,23,38,42,43,46,51-54]. Additionally, May et al. [55] found male sex, age > 40 years and severe anemia to be prognostic. Interestingly, active tuberculosis was not a risk factor for poor survival in our cohort, although tuberculosis has been estimated to cause about one third of all deaths of HIV-infected individuals in sub-Saharan Africa [4,43,52]. However, our study may be underpowered to detect differences in survival as only few patients had tuberculosis. Noteworthy, patients with tuberculosis were enrolled for treatment at higher CD4 cell counts. All patients had a mandatory adherence supporter, but data collection on adherence itself was inconsistent. Hence, we could not analyze adherence in this setting as in comparable African settings [14,24,25,46], where good adherence was shown to be associated with improved outcome under cART.

In our study, a considerable proportion of patients died or was lost to follow-up adding up to 21.7% during the first year of cART. Three comprehensive reviews [56-58] showed that attrition was highest during the first year on cART and 12-months’ retention rate ranged between 55%-93% [56-58] with an average rate of 75.2%-77.5% [57,58], which was comparable to our evaluation. Loss to follow-up was found to be more likely in individuals with WHO stage 4, CD4 cell count less than 50 cells/μl [42,43,51] and within the first 3 months of starting cART [47,51]. We assume that a significant part of these patients have died as an evaluation by Brinkhof showed [29]. The remote rural setting with distances up to 150 kilometers from the treatment centre may have contributed to this result [23,59]. Nevertheless, the 1-year survival on cART was comparable with other studies including urban settings [8,35,42,47,51-58].

Limitations and strengths
We acknowledge some limitations of our study. First, data on follow-up was not complete for all patients, possibly leading to an overestimation of cART effectiveness in this setting. Secondly, a significant proportion of patients were lost to follow-up (14.8%). However, as we considered that these latter patients experienced treatment failure this may have accounted for an underestimation of cART effectiveness. Thirdly, viral load could not be measured which has important implications for the definition of treatment failure. Moreover, the exact cause of death was not known in 43% of all patients. This may have lead to a survival bias as tuberculosis may have accounted for a substantial proportion of deaths. Adherence could not be included in our analysis due to inconsistency of data. Due to the large proportion of missing data for certain variables, we could not include all investigated factors in the multivariate analysis. WHO’s 2010 guidelines [60] promote tenofovir as one of the first line compounds of cART, which limits the relevance of our data to a certain extent. Nevertheless, stavudine will probably remain for a while due to its low costs, wide availability and being an alternative
compound in a setting with a relevant prevalence of HIV-associated nephropathy [61-63] and increasing prevalence of arterial hypertension and diabetes mellitus contributing to impaired renal function. This may especially be relevant in settings with high prevalence of anemia due to malaria and nutritional deficiencies where zidovudine can’t be readily used.

The strengths of our study are manifold. The care and treatment facility at St. Francis Designated District Hospital is among the largest centers offering cART in a remote rural setting of Eastern Africa. Data was collected prospectively allowing more precise assessment of treatment efficacy. Data was derived from one centre therefore avoiding any leveling effects and high heterogeneity. Also, our site strictly follows the Tanzanian guidelines of the NACP and was uniquely supplied by the NACP which directly reflects a reach-out antiretroviral treatment programme with a public health approach. All individuals in this study were treatment-naïve at the start of cART. Therefore, results are not affected by previous exposure to antiretrovirals. Finally, our cohort is one of the largest rural HIV-cohorts in sub-Saharan Africa [13,23-27] showing a 1-year survival on cART similar to studies performed in urban settings [8,35,42,46,51,52], where education is higher, infrastructures, skilled human resources, patient support and referral systems are better than in a rural setting. Starting cART with the support of a treatment assistant may have helped to overcome many of the above mentioned constraints of a rural setting [64,65]. These findings strongly support the feasibility of WHO’s policy of “rolling and reaching out” [5] to rural sites in sub-Saharan Africa.

Conclusions
In conclusion, cART initiation at higher CD4 cell counts and better general health condition can reduce HIV related mortality in a rural African setting. The principle of starting cART only with a treatment assistant may help to overcome the constraints of a rural setting and allows comparable treatment outcomes as in urban cohorts. Efforts must be made to promote earlier HIV diagnosis in order to start cART timely and improve survival in rural African regions with moderate to high HIV prevalence. This necessitates wider voluntary HIV testing and counselling.

Acknowledgements
We thank all the clinic and hospital staff, community partners and institutions that contributed to our study. We gratefully acknowledge the invaluable contributions of all patients in the Kilombero Valley who participated in this study. This research is an output of the Chronic Disease Clinic of Ifakara (CDCI), the St. Francis Designated District Hospital (SFDDH), the Ifakara Health Institute (IHI), the Swiss Tropical and Public Health Institute (SwissTPH), the Division of Infectious Diseases & Hospital Epidemiology of the University Hospital Basel and the Division of Infectious Diseases of the University Hospital Berne in the framework of a North-South collaboration. The study was funded by the Development Fund of the Kanton Basel Stadt, Basel Land and Solothurn, Switzerland.

Author details
1 St. Francis Designated District Hospital, Ifakara, United Republic of Tanzania. 2 Ifakara Health Institute, Ifakara, United Republic of Tanzania. 3 Ifakara Health Institute, Dar es Salaam, United Republic of Tanzania. 4 Swiss Tropical and Public Health Institute, University Basel, Basel, Switzerland. 5 Division of Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. 6 Division of Infectious Diseases, University Hospital and University of Berne, Berne, Switzerland.

Authors’ contributions
The authors designed and executed the study, had full access to the raw data, performed all analyses, wrote the article and had full responsibility for the decision to submit for publication. All authors contributed to the design of the present analysis and to the final draft of the article. The authors EM, MS, EGM and EC were members of the Chronic Disease Clinic of St. Francis Designated District Hospital at Ifakara, Kilombero District, United Republic of Tanzania and were actively involved in the management of patients and the collection of data. EM completed the first draft of the article. LE performed the statistical analyses.

Competing interests
The authors declare that they have no competing interests.

Received: 23 September 2010  Accepted: 19 April 2011
Published: 19 April 2011

References
1. Egger M, Hirschel B, Francioli P, et al: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss Cohort Study. BMJ 1997, 315:1194-95.
2. WHO: Treating 3 million by 2005: making it happen. [http://www.who.int/3by5/publications/documents/en/3by5StrategyMakingItHappen.pdf], Accessed 10 January 2011.
3. WHO: Scaling-up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach-2003 revision. 2004 [http://www.who.int/hiv/pub/prev_care/en/anrrevision2003en.pdf], Accessed 10 January 2011.
4. UNAIDS: Report on the global AIDS epidemic. Joint United Nations Programme on AIDS, Geneva; 2010 [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20101123_globalreport_en[1].pdf], Accessed 28th March 2011.
5. WHO: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva, Switzerland: WHO; 2007 [http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf], Progress Report. Accessed 10th January 2011.
6. Djomand G, Roels T, Ellerbrock T, et al: Virologic and immunologic outcome and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote D’Ivoire. AIDS 2003, 17(Suppl 3):S5-S15.
7. Marins J, Jamal L, Chen S, et al: Dramatic improvement of survival among adult Brazilian AIDS patients. AIDS 2003, 17:1675-82.
8. Cotzee D, Hildebrand K, Boule A, et al: Outcome after 2 years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18:887-95.
9. Ivers L, Kendrick D, Doucette K: Efficacy of antiretroviral therapy programmes in resource-poor settings: a meta-analysis of the published literature. CID 2003, 34:217-24.
10. Tubi S, Harrison L, Spinz E, et al: Predictors of virologic failure in HIV-1 infected patients starting highly active antiretroviral therapy in Porto Allegre, Brazil. Journal of Acquired Immune Deficiency Syndrome 2005, 40:324-28.
11. Braatstein P, Brinkhof M, Dabis F, et al: Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-24.
12. Stringer J, Zulu I, Levy J, et al: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782-93.
13. Lawn S, Myer L, Bekker L, et al: CD4 cell count recovery among HIV-infected patients with advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis 2006; 6:59.

14. Ferradini L, Jeannin A, Pinoges L, et al: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1333-42.

15. Kilaru K, Kumar A, Sippy N, et al: Antiretroviral therapy in low-income countries (ART-LINC) collaboration. Journal of Acquired Immune Deficiency Syndrome 2007, 45:S2-9.

16. Madec Y, Laureillard D, Pinoges L, et al: Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007; 21:351-59.

17. Tuboi S, Brinkhof M, Egger M, et al: Discordant responses to potent antiretroviral treatment in previously HIV-1-infected adults initiating treatment in resource-constraint countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. Journal of Acquired Immune Deficiency Syndrome 2007, 45:S2-9.

18. UNAIDS: Report on the global AIDS epidemic. Joint United Nations Programme on AIDS, Geneva, 2008 [http://www.unaids.org/en/ KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp], Accessed 10th January 2011.

19. Tanzania Commission for AIDS. UNGASS country progress report Tanzania - 2008: Business plan 4.0. [http://www.nacp.go.tz/modules/doc_sm/docs_by_type.php?doc_id=2750], Accessed 10th January 2011.

20. The United Republic of Tanzania: HIV/AIDS care and treatment plan 2003 - 2008: Business plan 4.0. [http://www.distincthealthservice.com/doc/32493303.pdf], Accessed 10th January 2011.

21. Barongo L, Borgdorff M, Mossdorf et al: The epidemiology of HIV-1 infection in urban areas, roadside settlements and rural villages in Mwanza Region, Tanzania. AIDS 1992, 6(12):1521-28.

22. Hunter D: AIDS in Sub-Saharan Africa: the epidemiology of heterosexual transmission and the prospect for prevention. Epidemiology 1996, 4:63-72.

23. Barth R, van der Meer J, Hoepelman A, et al: Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 2008, 27:977-84.

24. Bajunirwe F, Arts E, Tisch D, et al: Adherence and treatment response among HIV-1-infected Adults receiving antiretroviral therapy in a rural government hospital in South-western Uganda. Journal of the International Association of Physicians in AIDS Care 2009, 8(2):139-47.

25. Weidle P, Namai N, Solberg P, et al: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368:1587-94.

26. Johanssenn A, Naman E, Kivuyo S, et al: Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infectious Diseases 2009, 9(108) [http://www.biomedcentral.com/1471-2334/9/108], Accessed 10th January 2011.

27. Weidle P, Namai N, Solberg P, et al: Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368:1587-94.

28. Johanssenn A, Naman E, Ngowi B, et al: Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infectious Diseases 2008, 8(52) [http://www.biomedcentral.com/1471-2334/8/52], Accessed 10th January 2011.

29. Stoeckle M, Mchomvu R, Hatz C, et al: Moving up from 3 by 5. Lancet Infect Dis 2008, 8(5):353-361.

30. WHO: Guidelines for Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendation for a public health approach, 2006 revision. [http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf], Accessed 10th January 2011.
therapy in resource-limited settings. AIDS Research and Human Retroviruses 2008, 24:555-60.

53. MacPherson P, Moshabela M, Martinson N, et al: Mortality and loss to follow-up among HAART initiators in rural South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene 2009, 103:588-93.

54. Lawn S, Harries A, Aglaret X, et al: Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008, 22:187-1908.

55. May M, Boule A, Phiri S, et al: Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010, 376:449-57.

56. Rosen S, Fox M, Gill C: Patient retention in antiretroviral therapy programs in Sub-Saharan Africa: a systematic review. PLoS Medicine 2007, 4(10) [http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0040298], Accessed 10th January 2011.

57. Fox M, Rosen S: Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Tropical Medicine & International Health 2010, 15(suppl 1):1-15.

58. Tassie JM, Bajaj P, Vitoria M, et al: Trends in retention on antiretroviral therapy programs in low-income and middle-income countries. J Acquir Defic Syndr 2010, 54(4):437-41.

59. Bedelu M, Ford N, Hilderbrand K, et al: Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007, 196(suppl 3):464-8.

60. WHO: Guidelines for Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendation for a public health approach, 2010 revision[http://whqlibdoc.who.int/publications/2010/9789241599818_eng.pdf], Accessed 10th January 2011.

61. Han T, Naicker S, Ramdial P, et al: A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney International 2006, 69:2243-50.

62. Wools-Kaloustian K, Gupta S, Muloma E, et al: Renal disease in an antiretroviral-naive HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant 2007, 22:2208-13.

63. Naicker S, Fabian J: Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrology 2010, 74(1):51-56.

64. Wouters E, Van Damme W, van Rensburg D, et al: Impact of baseline health and community support on antiretroviral treatment outcomes in HIV patients in South Africa. AIDS 2008, 22:2245-48.

65. Nachega J, Chaisson R, Golub M, et al: Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010, 24:1273-80.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/11/98/prepub
doi:10.1186/1471-2334-11-98
Cite this article as: Mossdorf et al: Improved antiretroviral treatment outcome in a rural African setting is associated with CART initiation at higher CD4 cell counts and better general health condition. BMC Infectious Diseases 2011 11:98.

Submit your next manuscript to BioMed Central and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at www.biomedcentral.com/submit